Nalmefene for reduction of alcohol consumption in specific target populations
AssigneeH. Lundbeck A/S
InventorsLars Torup, Afsaneh Abbariki, Anna Bladström, Christine Persson, Didier Meulien, Per Sørensen, Thomas Jon Jensen, Jette Buch Østergaard
Life of this patent
Estimating the term…
Abstract
The present invention relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who has a high drinking risk level. The present invention also relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who maintains at least medium DRL after an observation period following initial assessment.
Claims31
1-27. (canceled)
A method for reducing alcohol consumption in a patient with alcohol dependence who has a high DRL, which method comprises administering a therapeutically effective amount of nalmefene to said patient.
A method for reducing alcohol consumption in a patient with alcohol dependence who maintains at least medium DRL after an observation period following initial assessment, which method comprises the administration of a therapeutically effective amount of nalmefene to said patient.
A method of reducing alcohol consumption in a patient who maintains at least medium DRL after an observation period in accordance with clinical practice, which method comprises the administration of a therapeutically effective amount of nalmefene to said patient.
A method for reducing of alcohol consumption in a patient with alcohol dependence, wherein said method comprises the following steps:
- a) identifying a patient with alcohol dependence i) who has a high DRL, and ii) who maintains a high DRL after an observation period following initial assessment, and
- b) administering a therapeutically effective amount of nalmefene to the patient identified in step a), wherein said nalmefene is administered as-needed.
Dependencies are inferred from the claim text.